NCT02931110View on ClinicalTrials.gov

Study of IV CBL0137 in Previously Treated Hematological Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Hematological Malignancies
Interventions
DRUG

CBL0137

CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

30912

Claude Sportes, Augusta

44106

University Hospitals Case Medical, Cleveland

90603

The Oncology Institute of Hope & Innovation, Whittier

Sponsors

Lead Sponsor

Incuron
All Listed Sponsors
lead

Incuron

INDUSTRY